Compliance
Claims review for Conexeu Sciences: regulatory status, the line every claim carries, and the passages on conexeu.com that match the claims rules, from the crawl of Nov 12.
27 passages on conexeu.com match a claims-scan rule; the widest, “Breakthrough”, appears on 44 pages. Each needs a reviewer’s call before anything is changed.
- 27 distinct passages to review
- 62 of 62 crawled pages carry at least one
- 3 of 5 scan rules matched something
- 0 crawled pages without the status line (R6)
Go through each passage below with client counsel and mark it Not a claim or Fix requested. A fix request lands on My plan.
Regulatory status
From the client profile. Everything said about CXU has to fit inside it.
CXU is an investigational medical device candidate in preclinical development. It has not been submitted to or reviewed by the U.S. Food and Drug Administration. Safety and effectiveness have not been established.
The line that travels with every claim
Rule R6: at first substantive mention, not only in a footer. On social, in the post copy itself.
CXU is an investigational medical device candidate in preclinical development. It has not been submitted to or reviewed by the U.S. Food and Drug Administration. Safety and effectiveness have not been established.
62 of 62 crawled pages carry a status line · crawl Nov 12
Findings on conexeu.com
Grouped by scan rule. A finding is a passage to review, not a confirmed violation: some are third-party headlines, biographies or disclaimers that quote the term. Negations such as “has not been approved for” are skipped by the crawler (the scrub list is the exception: a retired term is flagged wherever it appears). The same passage on many pages counts once.
Saved in this browser · 27 need review
Retired or prohibited term
Scrub list Terms retired from the brand or prohibited outright.
No passage matched this rule in the latest crawl.
Performance number
R2 R2: No results and no performance numbers.
No passage matched this rule in the latest crawl.
Approval language
R1/R6 R1: No outcome claims. R6: Status disclosure travels with the claim. 3 passages across 3 pages.
-
…‘next-generation’ aesthetics platform, raised $10M+ pre-Series A, and FDA approved in Sept ’25. Member of Galderma’s Executive Leadership Team that craf…
Reviewer call -
…ylane®, Cetaphil®, Differin®, Proactiv® and Epiduo®. Attained the 1st FDA-approved RX-to-OTC acne switch in 30 years. SVP and VP for Novartis across mul…
Reviewer call -
…ent and regulatory requirements for the intended application. Is CXU™ FDA approved? No. CXU™ is an investigational medical device candidate and has not…
Reviewer call
Outcome verb
R1 R1: No outcome claims. 3 passages across 3 pages.
-
…t, designed to flow, integrate and regenerate. 9,3,6 Flow Immediately restores lost volume Allows for native tissue ingrowth Slowly degraded by the…
Reviewer call -
…ce between volumization and tissue regeneration? Volumization adds or restores physical volume. Tissue regeneration involves biological processes th…
Reviewer call -
…ing the next evolution of regenerative tissue by delivering scalable, clinically proven and economically viable ‘collagen-based solutions’ that minimize risk…
Reviewer call
Uncaveated superlative
R7 R7: Superlatives are caveated. 21 passages across 62 pages.
-
…Rick Orford July 20, 2026 Conexeu Sciences: The Regenerative Medicine Breakthrough That Could Transform Healthcare CEO Miles Harrison on why the CXU™ pl…
Reviewer call -
…Directors. Conexeu November 20, 2025 Conexeu Sciences Signals a Major Breakthrough in ‘Personalized Human Tissue Creation’ Conexeu Sciences Inc. achieve…
Reviewer call -
…established. See Forward-Looking Cautionary Statement.Terms such as 'next-generation,' 'advanced,' 'innovative,' and 'bioregenerative' reflect the Company…
Reviewer call -
…ly 20, 2026 MEDIA YouTube Conexeu Sciences: The Regenerative Medicine Breakthrough That Could Transform Healthcare CEO Miles Harrison on why the CXU™ pl…
Reviewer call -
…son November 20, 2025 PRESS RELEASES Conexeu Sciences Signals a Major Breakthrough in ‘Personalized Human Tissue Creation’ Conexeu Sciences Inc. achieve…
Reviewer call -
…company. 8-Figure Exit, Novaestiq Corp. Co-Founder & CEO, built the ‘next-generation’ aesthetics platform, raised $10M+ pre-Series A, and FDA approved in…
Reviewer call -
…established. See Forward-Looking Cautionary Statement. Terms such as 'next-generation,' 'advanced,' 'innovative,' and 'bioregenerative' reflect the Company…
Reviewer call -
…Aesthetics Overview The CXU device candidate is being developed as a next-generation injectable matrix for tissue regeneration, designed to move beyond co…
Reviewer call -
…h Purpose. Backed by Science. At Conexeu, we are developing CXU™ as a next-generation collagen-based ECM platform for tissue regeneration, designed to move…
Reviewer call -
…-architecting-bioregeneration-tm) - [Conexeu Sciences signals a major breakthrough in personalized human tissue creation](https://www.conexeu.com/resour…
Reviewer call -
…n](https://www.conexeu.com/resources/conexeu-sciences-signals-a-major-breakthrough-in-personalized-human-tissue-creation) ## Optional - [A $190 billion…
Reviewer call -
…ercial biotechnology company redefining regenerative medicine through next-generation collagen science, announces the appointment of Miles D. Harrison as P…
Reviewer call -
…nctional restoration of native tissue. Our CXU™ platform represents a next-generation liquid extracellular matrix, which provides a complex and bioactive s…
Reviewer call -
…a biotechnology innovator redefining regenerative medicine through a next-generation collagen-based platform, today announced the appointments of Aaron Fa…
Reviewer call -
…the kind of responsible, purpose-driven progress that will define the next generation of biotechnology.” Read Original Release: https://www.newsfilecorp.co…
Reviewer call -
…partnerships, its start-up entities, and through major initiatives in breakthrough technologies, such as tissue engineering, cell therapies, diagnostics…
Reviewer call -
…sents an important achievement for Conexeu and our mission to advance breakthrough regenerative tissue technologies,” said Conexeu Co-Founder and Chief…
Reviewer call -
Conexeu Sciences Signals a Major Breakthrough in ‘Personalized Human Tissue Creation’ | Conexeu MENU CLOSE New 12-M…
Reviewer call -
…e 3D B.R.E.A.S.T.™ Back to Resources Conexeu Sciences Signals a Major Breakthrough in ‘Personalized Human Tissue Creation’ Conexeu Sciences Inc. achieve…
Reviewer call -
Conexeu Sciences: The Regenerative Medicine Breakthrough That Could Transform Healthcare | Conexeu MENU CLOSE New 12-Month Pre…
Reviewer call -
…to Resources Rick Orford Conexeu Sciences: The Regenerative Medicine Breakthrough That Could Transform Healthcare CEO Miles Harrison on why the CXU™ pl…
Reviewer call
No findings with this reviewer call.
Claims register
The verbs CXU copy may use, and what each replaces.
Approved lines
Cleared for use as written. Copy them rather than paraphrase.
- Architecting Bioregeneration
- Designing the blueprint for bioregeneration
- Understanding your tissue is the first step toward regenerating it.
- Designed with purpose. Backed by science.
- What if science could help you rebuild yourself?
- One platform, one formula, one device.
- What makes bioregeneration possible?
Claims rules
8 rules from the client profile. The scan rules above test the website against R1, R2, R6 and R7 and the scrub list; the rest need a person.